Preview Mode Links will not work in preview mode

Evidence Based Medicine presented by InpharmD™

  1. All Episodes
  2. Could SER-109 be an Answer for Recurrent C.Difficile Infection?

Could SER-109 be an Answer for Recurrent C.Difficile Infection?

Feb 22, 2022

A phase 3, double-blind, randomized, placebo-controlled trial conducted to show superiority of SER-109 in reducing the risk of C. difficile infection recurrence up to 8 weeks after treatment.